Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.
- Published in:
- Journal of the Endocrine Society, 2020, v. 4, n. 1, p. N.PAG, doi. 10.1210/jendso/bvz015
- By:
- Publication type:
- Article
Works by Udata, Chandrasekhar
Results: 11
1
2
A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 7, p. 855, doi. 10.1002/jcph.867
- By:
- Publication type:
- Article
3
Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 6, p. 643, doi. 10.1177/0091270009335768
- By:
- Publication type:
- Article
4
Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants.
- Published in:
- Journal of Clinical Pharmacology, 2009, v. 49, n. 6, p. 643, doi. 10.1177/0091270009335768
- By:
- Publication type:
- Article
5
A mechanistic pharmacokinetic model with drug and antidrug antibody interplay, and its application for assessing the impact of immunogenicity response on bioequivalence testing.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 11, p. 2182, doi. 10.1111/bcp.14312
- By:
- Publication type:
- Article
6
Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes.
- Published in:
- AAPS Journal, 2020, v. 22, n. 2, p. 1, doi. 10.1208/s12248-019-0401-3
- By:
- Publication type:
- Article
7
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
- Published in:
- Expert Review of Clinical Immunology, 2018, v. 14, n. 4, p. 329, doi. 10.1080/1744666X.2018.1446829
- By:
- Publication type:
- Article
8
Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
- Published in:
- Endocrine (1355008X), 2018, v. 62, n. 2, p. 371, doi. 10.1007/s12020-018-1597-1
- By:
- Publication type:
- Article
9
Xyntha<sup>®</sup> is effective and safe in previously treated patients with severe haemophilia A: Final results of a pivotal phase III study.
- Published in:
- 2009
- By:
- Publication type:
- Abstract
10
Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 1, p. 261, doi. 10.1002/cpt.3455
- By:
- Publication type:
- Article
11
Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents.
- Published in:
- 2021
- By:
- Publication type:
- Editorial